Loading
A phase 1/2 trial of Dose Escalation in advanced solid tumours, run by GeneQuantum Healthcare (Suzhou) Co., Ltd., now recruiting.
A Study of GQ1010 in Subjects With Advanced Solid Tumors. ClinicalTrials.gov record last updated 2025-02-10: recruiting. Enrollment is planned at 260 participants. Primary completion is estimated at 2028-05-23. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Dose Escalation, Dose Expansion1, Dose Expansion2, Dose Expansion3, phase II. Registered primary measures: Phase I/II: Incidence and Severity of Adverse Events (AEs); Phase Ia: Dose Limiting Toxicities (DLTs); Phase Ia: Maximal Tolerance Dose (MTD) or recommended doses for dose expansion (RDEs).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares BHV-1510, TROP2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares GeneQuantum Healthcare (Suzhou) and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares TROP2, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/